Trial of Advance Care Planning (ACP) & Goals of Care Designations (GCD) Discussions
Launched by UNIVERSITY OF ALBERTA · Jun 1, 2015
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Background: Respecting patients' preferences for treatment is a key component of high quality end of life care. Alberta Health Services (AHS) has developed tools for public, patient and healthcare provider (HCP) engagement and education (such as guidebooks, videos, and HCP training modules) to support widespread engagement in advance care planning (ACP) and determining Goals of Care Designation (GCD). However, none of these knowledge translation (KT) tools have been validated and they have not been tailored to reflect barriers in the local context.
ACP is defined as a communication process...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * diagnosis of either:
- • 1. heart failure classified as Class III or IV based on New York Heart Association Functional Classification or classified as Stage D based on American Heart Association/American College of Cardiology Heart Failure Classification;
- • 2. renal failure and on dialysis; or
- • 3. metastatic lung, gastrointestinal (including pancreatic) or gynecological cancer and on chemo, radiation therapy or palliative
- • 19 or over
- • able to communicate in English
- • reside within 100 km of Edmonton or Calgary
- • owns a phone
- Exclusion Criteria:
- • cognitive impairment which would impact ability to give informed consent
- • in crisis
- • first visit or in the case of renal patients, in the first month of dialysis
- • participated in ACP pilot study
- • visual and/or hearing impairment that would impact their ability to see and/or hear the Videos, and/or complete the assessments including the telephone follow-up interviews.
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Konrad Fassbender, PhD
Principal Investigator
University of Alberta
Sara Davison, MD, MHSc (Bioethics)
Principal Investigator
University of Alberta
Jessica Simon, MD
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials